STOCK TITAN

[SC14D9C] Durect Corp SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SC14D9C
Rhea-AI Filing Summary

DURECT Corporation filed a Schedule 14D-9C to disclose Amendment No.1 to the Agreement and Plan of Merger, dated August 8, 2025, which extends the date by which BHC Lyon Merger Sub must commence the tender offer under the previously announced Merger Agreement dated July 28, 2025. The filing states the amendment is attached as Exhibit 2.1 and incorporates a Current Report filed on August 8, 2025 as Exhibit 99.1.

The communication clarifies the tender offer has not commenced, is not an offer or solicitation, and that Parent and Merger Sub will file a Schedule TO and the Company will file a Schedule 14D-9 when the offer is launched. The filing directs investors to the SEC website and the Company’s investor site for tender materials and includes a detailed cautionary statement listing risks that could delay or prevent completion of the transaction.

DURECT Corporation ha depositato uno Schedule 14D-9C per comunicare la Modifica n.1 all'Agreement and Plan of Merger, datata 8 agosto 2025, che proroga il termine entro il quale BHC Lyon Merger Sub deve avviare l'offerta pubblica di acquisto prevista dal Merger Agreement annunciato il 28 luglio 2025. Il deposito specifica che la modifica è allegata come Exhibit 2.1 e incorpora un Current Report depositato l'8 agosto 2025 come Exhibit 99.1.

La comunicazione precisa che l'offerta non è stata ancora avviata, non costituisce un'offerta né una sollecitazione e che la società madre (Parent) e la Merger Sub presenteranno uno Schedule TO, mentre la Società depositerà uno Schedule 14D-9 al lancio dell'offerta. Il deposito rimanda gli investitori al sito della SEC e alla sezione investor della Società per i materiali relativi all'offerta e contiene un dettagliato avviso di rischio che elenca i fattori che potrebbero ritardare o impedire il completamento della transazione.

DURECT Corporation presentó un Schedule 14D-9C para dar a conocer la Enmienda n.º1 al Agreement and Plan of Merger, con fecha del 8 de agosto de 2025, que amplía el plazo en el que BHC Lyon Merger Sub debe iniciar la oferta pública de adquisición prevista en el Merger Agreement anunciado el 28 de julio de 2025. La presentación indica que la enmienda se adjunta como Exhibit 2.1 e incorpora un Current Report presentado el 8 de agosto de 2025 como Exhibit 99.1.

La comunicación aclara que la oferta no se ha iniciado, no constituye una oferta ni una solicitud y que la sociedad matriz (Parent) y la Merger Sub presentarán un Schedule TO y la Compañía presentará un Schedule 14D-9 cuando se lance la oferta. El documento remite a los inversores al sitio web de la SEC y a la sección de inversores de la Compañía para obtener los materiales de la oferta e incluye una declaración de advertencia detallada que enumera los riesgos que podrían retrasar o impedir la finalización de la transacción.

DURECT Corporation는 2025년 8월 8일자 Agreement and Plan of Merger에 대한 수정안(Amendment No.1)을 공개하기 위해 Schedule 14D-9C를 제출했으며, 이 수정안은 BHC Lyon Merger Sub가 2025년 7월 28일 발표된 Merger Agreement에 따라 공개매수(텐더 오퍼)를 개시해야 하는 기한을 연장합니다. 제출서류는 해당 수정안이 Exhibit 2.1로 첨부되었고, 2025년 8월 8일 제출된 Current Report가 Exhibit 99.1로 포함되어 있음을 명시합니다.

해당 공시는 공개매수가 아직 개시되지 않았고 제안이나 권유가 아님을 명확히 하며, 공개매수가 시작될 경우 모회사(Parent)와 Merger Sub가 Schedule TO를 제출하고 회사가 Schedule 14D-9를 제출할 것이라고 설명합니다. 제출서는 투자자들에게 공개매수 관련 자료를 SEC 웹사이트와 회사의 투자자 사이트에서 확인하라고 안내하며, 거래 완료를 지연시키거나 방해할 수 있는 위험요인들을 열거한 상세한 경고문을 포함하고 있습니다.

DURECT Corporation a déposé un Schedule 14D-9C pour divulguer l'Amendement n°1 à l'Agreement and Plan of Merger, daté du 8 août 2025, qui prolonge la date à laquelle BHC Lyon Merger Sub doit engager l'offre publique d'achat prévue par le Merger Agreement annoncé le 28 juillet 2025. le dépôt précise que l'amendement est joint en tant qu'Exhibit 2.1 et incorpore un Current Report déposé le 8 août 2025 en tant qu'Exhibit 99.1.

La communication indique clairement que l'offre n'a pas été lancée, qu'il ne s'agit ni d'une offre ni d'une sollicitation, et que la société mère (Parent) et la Merger Sub déposeront un Schedule TO et que la Société déposera un Schedule 14D-9 au lancement de l'offre. Le dépôt renvoie les investisseurs au site de la SEC et à la section investisseurs de la Société pour les documents relatifs à l'offre et inclut une mise en garde détaillée énumérant les risques pouvant retarder ou empêcher la réalisation de la transaction.

DURECT Corporation hat ein Schedule 14D-9C eingereicht, um Änderung Nr. 1 des Agreement and Plan of Merger vom 8. August 2025 offenzulegen, die die Frist verlängert, bis zu der BHC Lyon Merger Sub das zuvor am 28. Juli 2025 angekündigte Übernahmeangebot einleiten muss. Die Einreichung gibt an, dass die Änderung als Exhibit 2.1 beigefügt ist und einen am 8. August 2025 eingereichten Current Report als Exhibit 99.1 einbezieht.

Die Mitteilung stellt klar, dass das Übernahmeangebot noch nicht begonnen wurde, keine Aufforderung oder ein Angebot darstellt, und dass die Muttergesellschaft (Parent) und die Merger Sub ein Schedule TO einreichen werden und das Unternehmen ein Schedule 14D-9 bei Beginn des Angebots einreichen wird. Die Einreichung verweist Investoren auf die Website der SEC und die Investorenseite des Unternehmens für Angebotsunterlagen und enthält eine ausführliche Warnhinweis-Liste mit Risiken, die den Abschluss der Transaktion verzögern oder verhindern könnten.

Positive
  • Amendment disclosed publicly via Schedule 14D-9C with Exhibit 2.1 attached, demonstrating formal transparency to shareholders
  • Investor access ensured: tender materials will be filed with the SEC and made available on the SEC website and the Company’s investor site
Negative
  • Tender offer not commenced, so timing and completion remain uncertain
  • Filing explicitly lists material risks that could delay or prevent the transaction, including governmental approvals, shareholder participation uncertainty, and potential litigation
  • Amendment indicates a delay in the obligation to commence the tender offer, which may prolong uncertainty for stakeholders

Insights

TL;DR: Amendment extends the target start date for the tender offer; procedural disclosure with timing uncertainty for closing.

The Schedule 14D-9C serves primarily as a disclosure that Amendment No.1 (dated August 8, 2025) modifies the timing obligations under the Merger Agreement (dated July 28, 2025). The filing itself does not disclose changes to price, consideration, or other deal economics; it documents that the bidder has secured an extension to commence the tender offer. For deal participants and investors, the immediate effect is a timing shift rather than an economic change, preserving the transaction framework while creating additional uncertainty on closing timing.

TL;DR: The company provided formal disclosure and investor access to materials but highlights customary risks that could affect completion.

The filing emphasizes transparency by attaching the amendment and pointing shareholders to forthcoming tender offer materials and SEC filings. It reiterates standard corporate governance safeguards by warning shareholders that the tender offer has not commenced and by listing potential closing conditions and risks, including governmental approvals and possible litigation. These disclosures help inform shareholders of procedural status and risks without introducing new operational facts.

DURECT Corporation ha depositato uno Schedule 14D-9C per comunicare la Modifica n.1 all'Agreement and Plan of Merger, datata 8 agosto 2025, che proroga il termine entro il quale BHC Lyon Merger Sub deve avviare l'offerta pubblica di acquisto prevista dal Merger Agreement annunciato il 28 luglio 2025. Il deposito specifica che la modifica è allegata come Exhibit 2.1 e incorpora un Current Report depositato l'8 agosto 2025 come Exhibit 99.1.

La comunicazione precisa che l'offerta non è stata ancora avviata, non costituisce un'offerta né una sollecitazione e che la società madre (Parent) e la Merger Sub presenteranno uno Schedule TO, mentre la Società depositerà uno Schedule 14D-9 al lancio dell'offerta. Il deposito rimanda gli investitori al sito della SEC e alla sezione investor della Società per i materiali relativi all'offerta e contiene un dettagliato avviso di rischio che elenca i fattori che potrebbero ritardare o impedire il completamento della transazione.

DURECT Corporation presentó un Schedule 14D-9C para dar a conocer la Enmienda n.º1 al Agreement and Plan of Merger, con fecha del 8 de agosto de 2025, que amplía el plazo en el que BHC Lyon Merger Sub debe iniciar la oferta pública de adquisición prevista en el Merger Agreement anunciado el 28 de julio de 2025. La presentación indica que la enmienda se adjunta como Exhibit 2.1 e incorpora un Current Report presentado el 8 de agosto de 2025 como Exhibit 99.1.

La comunicación aclara que la oferta no se ha iniciado, no constituye una oferta ni una solicitud y que la sociedad matriz (Parent) y la Merger Sub presentarán un Schedule TO y la Compañía presentará un Schedule 14D-9 cuando se lance la oferta. El documento remite a los inversores al sitio web de la SEC y a la sección de inversores de la Compañía para obtener los materiales de la oferta e incluye una declaración de advertencia detallada que enumera los riesgos que podrían retrasar o impedir la finalización de la transacción.

DURECT Corporation는 2025년 8월 8일자 Agreement and Plan of Merger에 대한 수정안(Amendment No.1)을 공개하기 위해 Schedule 14D-9C를 제출했으며, 이 수정안은 BHC Lyon Merger Sub가 2025년 7월 28일 발표된 Merger Agreement에 따라 공개매수(텐더 오퍼)를 개시해야 하는 기한을 연장합니다. 제출서류는 해당 수정안이 Exhibit 2.1로 첨부되었고, 2025년 8월 8일 제출된 Current Report가 Exhibit 99.1로 포함되어 있음을 명시합니다.

해당 공시는 공개매수가 아직 개시되지 않았고 제안이나 권유가 아님을 명확히 하며, 공개매수가 시작될 경우 모회사(Parent)와 Merger Sub가 Schedule TO를 제출하고 회사가 Schedule 14D-9를 제출할 것이라고 설명합니다. 제출서는 투자자들에게 공개매수 관련 자료를 SEC 웹사이트와 회사의 투자자 사이트에서 확인하라고 안내하며, 거래 완료를 지연시키거나 방해할 수 있는 위험요인들을 열거한 상세한 경고문을 포함하고 있습니다.

DURECT Corporation a déposé un Schedule 14D-9C pour divulguer l'Amendement n°1 à l'Agreement and Plan of Merger, daté du 8 août 2025, qui prolonge la date à laquelle BHC Lyon Merger Sub doit engager l'offre publique d'achat prévue par le Merger Agreement annoncé le 28 juillet 2025. le dépôt précise que l'amendement est joint en tant qu'Exhibit 2.1 et incorpore un Current Report déposé le 8 août 2025 en tant qu'Exhibit 99.1.

La communication indique clairement que l'offre n'a pas été lancée, qu'il ne s'agit ni d'une offre ni d'une sollicitation, et que la société mère (Parent) et la Merger Sub déposeront un Schedule TO et que la Société déposera un Schedule 14D-9 au lancement de l'offre. Le dépôt renvoie les investisseurs au site de la SEC et à la section investisseurs de la Société pour les documents relatifs à l'offre et inclut une mise en garde détaillée énumérant les risques pouvant retarder ou empêcher la réalisation de la transaction.

DURECT Corporation hat ein Schedule 14D-9C eingereicht, um Änderung Nr. 1 des Agreement and Plan of Merger vom 8. August 2025 offenzulegen, die die Frist verlängert, bis zu der BHC Lyon Merger Sub das zuvor am 28. Juli 2025 angekündigte Übernahmeangebot einleiten muss. Die Einreichung gibt an, dass die Änderung als Exhibit 2.1 beigefügt ist und einen am 8. August 2025 eingereichten Current Report als Exhibit 99.1 einbezieht.

Die Mitteilung stellt klar, dass das Übernahmeangebot noch nicht begonnen wurde, keine Aufforderung oder ein Angebot darstellt, und dass die Muttergesellschaft (Parent) und die Merger Sub ein Schedule TO einreichen werden und das Unternehmen ein Schedule 14D-9 bei Beginn des Angebots einreichen wird. Die Einreichung verweist Investoren auf die Website der SEC und die Investorenseite des Unternehmens für Angebotsunterlagen und enthält eine ausführliche Warnhinweis-Liste mit Risiken, die den Abschluss der Transaktion verzögern oder verhindern könnten.

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14D-9

 

 

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

DURECT CORPORATION

(Name of Subject Company)

 

 

DURECT CORPORATION

(Name of Person(s) Filing Statement)

 

 

Common stock, par value $0.0001 per share

(Title of Class of Securities)

266605500

(CUSIP Number of Class of Securities)

James E. Brown

Chief Executive Officer

DURECT Corporation

10240 Bubb Road

Cupertino, CA 95014

(408) 777-1417

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

on Behalf of the Person(s) Filing Statement)

 

 

With copies to:

Stephen Thau

David Schwartz

Albert Vanderlaan

Orrick, Herrington & Sutcliffe LLP

51 West 52nd Street

New York, NY 10019

(212) 506-5076

 

 

 

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 
 


This Schedule 14D-9C filing relates solely to the below listed document disclosing the entry into that Amendment No. 1 to the Agreement and Plan of Merger, dated as of August 8, 2025, by and among DURECT Corporation, a Delaware corporation (the “Company”), BHC Lyon Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Bausch Health Americas, Inc., a Delaware corporation (“Parent”) to extend the date by which Merger Sub is obligated to commence the tender offer for all of the outstanding shares of common stock of the Company pursuant to the previously announced Agreement and Plan of Merger, dated as of July 28, 2025 (the “Merger Agreement”), by and among the Company, Parent, Merger Sub, and solely for purposes of Section 6.10 of the Merger Agreement, Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia:

 

   

Current Report on Form 8-K filed by the Company on August 8, 2025.

The document is attached as Exhibit 2.1 hereto.

EXHIBIT INDEX

 

Exhibit
No.
  

Description

99.1    Current Report on Form 8-K (incorporated by reference to the Company’s Current Report on Form 8-K, filed on August 8, 2025.


ADDITIONAL INFORMATION AND WHERE TO FIND IT

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of the Company. At the time the offer is commenced, Parent and Merger Sub will file a Tender Offer Statement on Schedule TO with the SEC, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The Company stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of the Company. In addition, all of these materials (and all other materials filed by the Company with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by the Company at https://www.durect.com/investors/.


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Company’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of the Company’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the effect of this announcement or pendency of the proposed transaction on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from the Company’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of the Company into Parent subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of the Company’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the SEC by the Company, including the Company’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by the Company and the tender offer documents to be filed by Parent and Merger Sub.

The Company is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as required by law.

FAQ

What did DURECT (DRRX) file in this Schedule 14D-9C?

The Company filed a Schedule 14D-9C disclosing Amendment No.1 dated August 8, 2025 to the Merger Agreement, which extends the date by which Merger Sub must commence the tender offer under the Merger Agreement dated July 28, 2025.

Has the tender offer for DRRX shares started?

No. The filing states the tender offer has not commenced and this communication is not an offer or solicitation.

Where can DRRX shareholders find the tender offer materials?

When available, materials will be filed with the SEC and can be obtained free of charge from the SEC website (www.sec.gov) and from DURECT’s investor site at https://www.durect.com/investors/.

Does the filing change the deal price or other economic terms?

The Schedule 14D-9C discloses an amendment extending the tender offer start date; it does not state any changes to price or other economic terms in the provided text.

What risks did DURECT highlight about the transaction?

The Company listed risks including timing uncertainty, the possibility the transaction may not be completed, governmental approvals delaying or preventing closing, uncertain stockholder tendering, potential litigation, integration challenges, and other business and economic risks.

Will Parent and Merger Sub file additional documents?

Yes. The filing states Parent and Merger Sub will file a Tender Offer Statement on Schedule TO when the offer is commenced, and the Company will file a Schedule 14D-9 in connection with the offer.
DURECT

NASDAQ:DRRX

DRRX Rankings

DRRX Latest News

DRRX Latest SEC Filings

DRRX Stock Data

57.74M
27.37M
11.82%
22.34%
2.46%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CUPERTINO